Esterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration
Advanced Materials · 2026-10 · 38 (59)
DOI: 10.1002/adma.74762 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 23.08.2026. Verfasst von Zeru Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, Universit…. Hauptthemen laut MEDLINE: Blood-Brain Barrier, RNA, Messenger, Cholesterol, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UTSW Proteomics Core, UTSW Small Animal Imaging Resource, NCI NIH HHS.
Abstract (Originalsprache)
The blood–brain barrier (BBB) plays a critical role in maintaining central nervous system homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. While most delivery strategies focus on crossing the BBB, targeting brain endothelial cells directly may offer a complementary and more controlled alternative for therapeutic intervention. This study presents a ligand‐free lipid nanoparticle (LNP) platform that enables efficient mRNA delivery to the brain endothelium via systemic administration. A modular synthesis strategy was used to generate a chemically diverse library of cholesterol‐based lipids. Screening of 486 LNPs identified an optimized four‐component formulation consisting of C6O2B2 (novel cholesterol‐based lipid), DODAP, DSPC, and DMG‐PEG, which achieves high transfection efficiency in brain endothelial cells without the incorporation of free cholesterol or disruption of BBB integrity and function, such as those utilized in focused ultrasound (FUS) techniques. This BBB‐targeting LNP platform avoids neuronal and glial transfection, thereby offering a noninvasive, and scalable approach for cerebrovascular gene delivery. The work establishes a new class of cholesterol‐based lipids and provides a foundation for next‐generation RNA therapeutics targeting BBB‐associated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Zeru Tian, Xu Wang, Alexis Pacheco Benitez, Erick Guerrero, Yaou Duan, Jingwen Wei, Lukas Farbiak, Daniel J Siegwart
Förderung
- UTSW Proteomics Core
- UTSW Small Animal Imaging Resource
- NCI NIH HHS
- Preclinical PET/MRI core
- NIBIB NIH HHS
- NIH HHS
- National Institutes of Health
- National Institute of Biomedical Imaging and Bioengineering
Zitieren
APA
Tian, Z., Wang, X., Benitez, A. P., Guerrero, E., Duan, Y., Wei, J., Farbiak, L., & Siegwart, D. J. (2026). Esterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration. Advanced Materials, 38(59). https://doi.org/10.1002/adma.74762
Vancouver
Tian Z, Wang X, Benitez AP, Guerrero E, Duan Y, Wei J, et al. Esterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration. Advanced Materials. 2026;38(59). doi:10.1002/adma.74762
BibTeX
@article{Tian2026,
author = {Tian, Zeru and Wang, Xu and Benitez, Alexis Pacheco and Guerrero, Erick and Duan, Yaou and Wei, Jingwen and Farbiak, Lukas and Siegwart, Daniel J},
title = {Esterified Cholesterol Conjugates Enable LNP‐Mediated mRNA Delivery to the Blood–Brain Barrier Following Intravenous Administration},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {59},
doi = {10.1002/adma.74762}
}
EUVIMED